Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 63-65 |
| Number of pages | 3 |
| Journal | Medicine Today |
| Volume | 17 |
| Issue number | 11 |
| Publication status | Published - 1 Nov 2016 |
Cite this
}
Idarucizumab : An anticoagulant reversal agent for dabigatran. / Brown, Anthony F. T.; Nandurkar, Harshal.
In: Medicine Today, Vol. 17, No. 11, 01.11.2016, p. 63-65.Research output: Contribution to journal › Review Article › Other › peer-review
TY - JOUR
T1 - Idarucizumab
T2 - An anticoagulant reversal agent for dabigatran
AU - Brown, Anthony F. T.
AU - Nandurkar, Harshal
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.
AB - Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.
UR - http://www.scopus.com/inward/record.url?scp=84997703700&partnerID=8YFLogxK
UR - http://medicinetoday.com.au/2016/november/regular-series/idarucizumab-anticoagulant-reversal-agent-dabigatran
M3 - Review Article
VL - 17
SP - 63
EP - 65
JO - Medicine Today
JF - Medicine Today
SN - 1443-430X
IS - 11
ER -